Qiagen N.V. $QGEN Shares Sold by Massachusetts Financial Services Co. MA

by · The Cerbat Gem

Massachusetts Financial Services Co. MA cut its stake in shares of Qiagen N.V. (NYSE:QGEN – Free Report) by 2.4% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 23,940,960 shares of the company’s stock after selling 584,113 shares during the period. Massachusetts Financial Services Co. MA owned about 10.77% of Qiagen worth $1,069,682,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in QGEN. MAI Capital Management increased its stake in shares of Qiagen by 998.9% during the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after purchasing an additional 889 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Qiagen by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after buying an additional 849 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after acquiring an additional 796 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Qiagen by 375.5% in the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after acquiring an additional 980 shares during the last quarter. Finally, Cullen Frost Bankers Inc. raised its stake in Qiagen by 13,144.4% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after purchasing an additional 1,183 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Down 1.5%

Shares of NYSE:QGEN opened at $47.64 on Friday. Qiagen N.V. has a 52-week low of $39.61 and a 52-week high of $54.61. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45. The business has a fifty day moving average of $48.17 and a two-hundred day moving average of $49.41. The stock has a market cap of $10.06 billion, a P/E ratio of 24.60, a PEG ratio of 2.19 and a beta of 0.66.

Qiagen (NYSE:QGEN – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.03. The firm had revenue of $532.58 million during the quarter, compared to analysts’ expectations of $525.68 million. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. Qiagen’s revenue was up 6.2% compared to the same quarter last year. During the same period last year, the business earned $0.60 earnings per share. On average, research analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on QGEN. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Citigroup downgraded Qiagen from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $57.89 to $52.63 in a report on Thursday, December 11th. Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Finally, Barclays reiterated an “overweight” rating and set a $57.89 price target (up from $55.79) on shares of Qiagen in a report on Monday, December 15th. Two analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $52.84.

Read Our Latest Analysis on Qiagen

About Qiagen

(Free Report)

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

Further Reading

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN – Free Report).